The Latin America, Middle East and Africa Cancer Gene Therapy Market is expected to witness market growth of 26.5% CAGR during the forecast period (2022-2028).
Several unmet medical needs for cancer treatment have prompted cancer gene therapy research and development. The global cancer gene therapy market is being driven by a number of factors, including rising cancer prevalence, increased government activities, and increased funding from numerous governments and non-government organizations. Furthermore, the cancer gene therapy market is being driven by the ethical acceptability of gene therapy for disease treatment and the increasing popularity of DNA vaccines. However, the global market for cancer gene therapy is being held back by a lack of awareness and the high expense of treatment.
The development of some novel therapies with a higher success rate is projected to provide a promising future for cancer gene therapy. Furthermore, despite the high costs of R&D, pharmaceutical corporations are becoming more interested in this subject. This is predicted to have a significant impact on the cancer gene therapy business. The majority of cancer gene therapy products are now in clinical trials. Following the clearance or success of these drugs in clinical trials, the market is likely to grow.
The Brazzaville Declaration on Noncommunicable Disease Prevention and Control in the WHO African Region, adopted in 2011, reaffirmed African governments' understanding of the growing health threat posed by non-communicable diseases (NCDs), such as cancer. The signatories agreed to develop prevention and control strategies, strengthen their health systems to reduce the burden of NCDs, source the funds needed to fight these diseases, and facilitate their national health information systems to produce information on NCDs and their risk factors, among other things. However, progress is still gradual in this direction. Only 17 of the 46 nations that responded to a WHO survey in the African region in 2010 had operational cancer policies, strategies, or action plans.
The Brazil market dominated the LAMEA Cancer Gene Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $87.5 million by 2028. The Argentina market anticipated to grow at a CAGR of 27.2% during (2022-2028). Additionally, The UAE market is expected to showcase a CAGR of 26.2% during (2022-2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
By Therapy
By Country
Several unmet medical needs for cancer treatment have prompted cancer gene therapy research and development. The global cancer gene therapy market is being driven by a number of factors, including rising cancer prevalence, increased government activities, and increased funding from numerous governments and non-government organizations. Furthermore, the cancer gene therapy market is being driven by the ethical acceptability of gene therapy for disease treatment and the increasing popularity of DNA vaccines. However, the global market for cancer gene therapy is being held back by a lack of awareness and the high expense of treatment.
The development of some novel therapies with a higher success rate is projected to provide a promising future for cancer gene therapy. Furthermore, despite the high costs of R&D, pharmaceutical corporations are becoming more interested in this subject. This is predicted to have a significant impact on the cancer gene therapy business. The majority of cancer gene therapy products are now in clinical trials. Following the clearance or success of these drugs in clinical trials, the market is likely to grow.
The Brazzaville Declaration on Noncommunicable Disease Prevention and Control in the WHO African Region, adopted in 2011, reaffirmed African governments' understanding of the growing health threat posed by non-communicable diseases (NCDs), such as cancer. The signatories agreed to develop prevention and control strategies, strengthen their health systems to reduce the burden of NCDs, source the funds needed to fight these diseases, and facilitate their national health information systems to produce information on NCDs and their risk factors, among other things. However, progress is still gradual in this direction. Only 17 of the 46 nations that responded to a WHO survey in the African region in 2010 had operational cancer policies, strategies, or action plans.
The Brazil market dominated the LAMEA Cancer Gene Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $87.5 million by 2028. The Argentina market anticipated to grow at a CAGR of 27.2% during (2022-2028). Additionally, The UAE market is expected to showcase a CAGR of 26.2% during (2022-2028).
Based on Therapy, the market is segmented into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on End User, the market is segmented into Hospitals, Diagnostic centers and Research Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, GlaxoSmithKline PLC (GSK), Amgen, Inc., Bristol Myers, Squibb Company, Karyopharm Therapeutics, Inc., Gilead Sciences, Inc., Adaptimmune Limited, Genelux Corporation, and Sarepta Therapeutics, Inc
Scope of the Study
Market Segments Covered in the Report:
By Therapy
- Gene Induced Immunotherapy
- Oncolytic Virotherapy, and
- Gene Transfer
- Hospitals
- Diagnostic centers
- Research Institutes
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Cancer Gene Therapy Market by Therapy
Chapter 4. LAMEA Cancer Gene Therapy Market by End User
Chapter 5. LAMEA Cancer Gene Therapy Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Novartis AG
- GlaxoSmithKline PLC (GSK)
- Amgen, Inc.
- Bristol Myers Squibb Company
- Karyopharm Therapeutics, Inc.
- Gilead Sciences, Inc.
- Adaptimmune Limited
- Genelux Corporation
- Sarepta Therapeutics, Inc.
Methodology
LOADING...
